IDL Biotech has appointed Subyung Park as Business Development Manager Asia with a focus on the product TUBEX® TF.
Read the press release here
IDL Biotech has appointed Subyung Park as Business Development Manager Asia with a focus on the product TUBEX® TF.
Read the press release here
This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA...
(In Swedish)
IDL Biotech wants to focus on rapid diagnostic tests and automated assays of its tumor markers. By licensing the platform ELISA to Beckman Coulter, we can focus our resources on streamlining and developing the other platforms, said Gunnar Wahlberg, CEO of IDL...